Journal for Re Attach Therapy and Developmental Diversities
eISSN: 2589-7799
2021 March; 4 (1): 127-139

An Integrative Review of Cancer: Etiology, Clinical Presentation, and Treatment Modalities in Modern Medicine and Ayurveda

Dr. Rashmi Gupta*

*Associate Professor, Department of Shalya Tantra, Faculty of Ayurveda, Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Varanasi 221005
Email- rashmi.gupta@bhu.ac.in
Phone No.-8299612869
ORCID Id-http://orcid.org/0000-0002-0558-9577

Abstract

Cancer constitutes a major global health burden, characterized by uncontrolled cellular proliferation and metastatic potential. This review provides a comprehensive analysis of cancer from modern and Ayurvedic perspectives. We delineate the modern understanding, covering its definition, incidence, multifactorial etiology, and common clinical presentations. The cornerstone treatment modalities of modern oncology—surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy—are detailed alongside their limitations, including systemic toxicity and resistance. Parallelly, the article explores the conceptualization of cancer in Ayurveda, often correlated with *Arbuda*, a condition arising from the aggravation of the *Tridoshas* (Vata, Pitta, Kapha) and the accumulation of *Ama* (toxins). The review synthesizes the principles of Ayurvedic management, including *Shodhana* (bio-purification), *Shamana* (palliation), and *Rasayana* (rejuvenation). We discuss the growing evidence supporting the role of these modalities as complementary care for mitigating side-effects of conventional treatments and improving quality of life. The conclusion underscores the promise of an integrative oncology model that synergizes the strengths of modern biomedical science with the holistic principles of Ayurveda. This paradigm warrants further rigorous preclinical and clinical investigation to establish standardized, evidence-based protocols for comprehensive cancer care.

Keywords: Cancer; Oncology; Neoplasms; Ayurveda; *Arbuda*; Integrative Medicine; Palliative Care; *Tridosha*; *Panchakarma*; *Rasayana*.

Introduction

Definition of Cancer

Cancer is a complex and multifaceted group of diseases characterized by the fundamental aberration of uncontrolled cellular growth and proliferation. At its core, cancer represents a breakdown in the regulatory mechanisms that normally govern cell division, differentiation, and death.

The modern understanding of cancer is powerfully encapsulated by the **"Hallmarks of Cancer"** framework, first proposed by Hanahan and Weinberg and subsequently updated. This conceptual model identifies a set of functional capabilities acquired by cells during the multistep process of tumorigenesis [1, 2]. The original hallmarks include:

Sustaining Proliferative Signaling: Cancer cells generate their own growth signals and are less dependent on external stimuli, often through oncogene activation.

Evading Growth Suppressors: They bypass powerful programs (e.g., those controlled by tumor suppressor genes like *p53* and *RB*) that would otherwise inhibit cell proliferation.

Resisting Cell Death: Cancer cells develop mechanisms to avoid apoptosis (programmed cell death), allowing for their continued survival.

Enabling Replicative Immortality: They activate mechanisms, primarily through the telomerase enzyme, to overcome the natural limits on cell divisions.

Inducing Angiogenesis: Tumors can co-opt the body's vascular system to stimulate the formation of new blood vessels, ensuring a supply of oxygen and nutrients.

Activating Invasion and Metastasis: This defining capability allows cancer cells to disseminate from the primary tumor, invade surrounding tissues, and colonize distant organs, which is the primary cause of death in most cancer patients.

The updated hallmarks include emerging core capabilities and enabling characteristics [2]:

7. **Deregulating Cellular Energetics:** Reprogramming energy metabolism to support rapid growth, often by switching to glycolysis even in the presence of oxygen (the Warburg effect).
8. **Avoiding Immune Destruction:** Cancer cells can evade detection and elimination by the host's immune system.
9. **Genome Instability and Mutation:** An underlying enabler of cancer, where increased mutability allows cells to acquire the necessary hallmarks more rapidly.

10. **Tumor-Promoting Inflammation:** Inflammatory cells and signaling molecules within the tumor microenvironment can foster proliferation, survival, and angiogenesis.
This malignant transformation is driven by accumulated genetic and epigenetic alterations. These changes can be inherited in the germline but are more frequently acquired somatically due to exposure to carcinogens, errors in DNA replication, or other environmental factors [1, 4]. The culmination of these hallmarks is a population of cells that proliferate autonomously, invade locally, and can metastasize to form secondary tumors at sites distant from the tissue of origin, ultimately leading to organ failure and mortality.

Incidence of Cancer
The global incidence of cancer represents a significant and growing public health challenge. According to the most recent estimates from the Global Cancer Observatory (GLOBOCAN), there were approximately **20 million new cancer cases** diagnosed worldwide in 2022 [6]. This figure underscores the pervasive nature of the disease across all geographic and socioeconomic regions.

The distribution of cancer types varies by sex, geography, and level of human development. The most commonly diagnosed cancers globally in 2022 were [6]:
Female breast cancer (2.3 million new cases)
Lung cancer (2.5 million new cases)
Colorectal cancer (1.9 million new cases)
Prostate cancer (1.5 million new cases)
Stomach cancer (970,000 new cases)

Significant geographic variations exist in cancer incidence. For example, lung cancer incidence rates are particularly high in Eastern Asia and Eastern Europe, reflecting historical patterns of tobacco use [7]. Cervical cancer incidence remains disproportionately high in sub-Saharan Africa and parts of South America, largely due to limited access to HPV vaccination and screening programs [8]. The incidence of liver cancer is elevated in Eastern Asia and Northern Africa, correlating with the prevalence of hepatitis B and C infections [9].

Over the past decades, global cancer incidence has shown a steady increase, driven by several factors [10, 11]:
Population growth and aging
Changing prevalence of risk factors (tobacco use, unhealthy diets, physical inactivity, alcohol consumption)
Improved cancer detection and registration in many regions
Environmental and occupational exposures

Projections indicate a continued rise in cancer incidence, with estimates suggesting **over 28 million new cases per year by 2040** [6]. This anticipated increase highlights the urgent need for enhanced prevention strategies, early detection programs, and sustainable cancer care systems worldwide.

Causes of Cancer
The development of cancer is a multifactorial process driven by a complex interplay of genetic, environmental, and lifestyle factors. The fundamental biological principle is the accumulation of genetic alterations that lead to the loss of normal cellular growth control. These causative factors can be broadly categorized as follows:

Genetic and Molecular Factors
Inherited Mutations: Approximately 5-10% of cancers are attributable to inherited germline mutations in high-penetrance cancer susceptibility genes. Examples include:
BRCA1* and *BRCA2: Associated with hereditary breast and ovarian cancer syndrome.
TP53 (Li-Fraumeni syndrome): Predisposes to a wide range of cancers.
DNA mismatch repair genes (e.g., *MLH1*, *MSH2*): Cause Lynch syndrome, increasing risk for colorectal and endometrial cancers [12].

Somatic Mutations: The vast majority of genetic alterations are acquired in somatic cells throughout a person's lifetime due to errors in DNA replication or exposure to carcinogens. These mutations can activate oncogenes (e.g., *RAS*, *MYC*) or inactivate tumor suppressor genes Figure 1 (e.g., *TP53*, *RB1*) [13].



(Figure:1)

Environmental and Occupational Exposures

Tobacco Smoke: The single greatest preventable cause of cancer worldwide, responsible for approximately 25% of cancer deaths. It is causally linked to cancers of the lung, larynx, oral cavity, pharynx, esophagus, pancreas, bladder, kidney, and others. Tobacco smoke contains over 70 known carcinogens, including polycyclic aromatic hydrocarbons and nitrosamines [14].
Infectious Agents: Chronic infections are estimated to cause about 13% of cancers globally. Key oncogenic pathogens include:
Helicobacter pylori (stomach cancer)
Human Papillomavirus (HPV) (cervical, oropharyngeal, anal cancers)
Hepatitis B and C viruses (HBV, HCV) (hepatocellular carcinoma)
Epstein-Barr virus (EBV) (associated with lymphomas and nasopharyngeal carcinoma) [15].
Radiation:
Ionizing Radiation: Such as from radon gas (a cause of lung cancer), medical imaging, and nuclear fallout.
Ultraviolet (UV) Radiation: From sunlight and tanning beds, is the primary cause of skin cancers (melanoma, basal cell carcinoma, squamous cell carcinoma) [16].
Occupational Carcinogens: Exposure to specific chemicals and fibers in the workplace, including asbestos (mesothelioma, lung cancer), benzene (leukemia), arsenic (skin, lung cancer), and certain dyes [17].

Lifestyle and Behavioral Factors

Dietary Factors: A diet high in processed meats, red meat, and saturated fats, and low in fruits, vegetables, and dietary fiber is associated with an increased risk of colorectal and other cancers. Aflatoxin contamination in foodstuffs is a potent risk factor for liver cancer [18].
Alcohol Consumption: The consumption of alcoholic beverages is a established risk factor for cancers of the oral cavity, pharynx, larynx, esophagus, liver, colorectum, and breast. Ethanol and its metabolite acetaldehyde are classified as carcinogens [18].
Obesity and Physical Inactivity: Excess body weight is a significant risk factor for an increasing number of malignancies, including postmenopausal breast, colorectal, endometrial, esophageal, pancreatic, and kidney cancers. The mechanisms involve chronic inflammation, altered levels of sex hormones, and insulin resistance [19].

Underlying Biological Condition

Chronic Inflammation: Persistent inflammatory states, even in the absence of infection, can promote carcinogenesis. Conditions include inflammatory bowel disease (colorectal cancer), chronic pancreatitis (pancreatic cancer), and gastroesophageal reflux disease (esophageal adenocarcinoma).
In summary, most cancers are caused by a combination of these factors acting together over time, often referred to as the "multiple-hit" hypothesis. The relative contribution of each factor varies significantly by cancer type and individual susceptibility.

Signs and Symptoms of Cancer
The signs and symptoms of cancer are highly variable and depend on the type, location, size, and stage of the disease, as well as the presence of metastases. They arise from the local effects of the primary tumor, systemic effects of the disease, or from metastatic spread to distant sites. Recognizing these indicators is crucial for prompting early diagnosis and investigation.
Local Symptoms (Due to the Primary Tumor)
Local symptoms are caused by the tumor mass invading or pressing on nearby tissues, organs, nerves, or blood vessels.
Unusual Lumps or Swelling: A persistent lump or area of thickening that can be felt under the skin (e.g., in the breast, testicle, or lymph nodes) [20].
Persistent Pain: Unexplained pain that does not go away, often a feature of bone cancer or cancers that press on nerves or organs [21].
Changes in Bowel or Bladder Habits: Persistent constipation, diarrhea, narrowing of stool, or changes in bladder function can indicate colorectal or urological cancers [22].
Unusual Bleeding or Discharge: This includes:
Hemoptysis (coughing up blood) in lung cancer.
Hematemesis (vomiting blood) or melena (black, tarry stools) in upper GI cancers.
Abnormal vaginal bleeding, particularly post-menopausal, in endometrial or cervical cancer.
Hematuria (blood in urine) in bladder or kidney cancer [23].
Persistent Cough or Hoarseness: A cough that does not resolve or hoarseness of voice can be a sign of lung, laryngeal, or thyroid cancer [24].
Skin Changes: This includes not only changes in a mole (suggestive of melanoma) but also jaundice (yellowing of skin and eyes) in liver or pancreatic cancer, and darkening of the skin (acanthosis nigricans) [25].

Systemic Symptoms (Constitutional Symptoms)
These are whole-body effects caused by the cancer's interaction with the body's metabolism and immune system.
Unexplained Weight Loss: Losing a significant amount of weight (e.g., 10 pounds or more) without trying is a common symptom of many cancers, often referred to as cancer cachexia [26].
Persistent Fatigue: Extreme, unrelenting tiredness that is not relieved by rest. This is one of the most common symptoms in advanced cancer [27].
Fever: Persistent or intermittent fevers, particularly at night, can be a sign of cancers like lymphoma or leukemia, or of an infection due to a compromised immune system [28].
Night Sweats: Drenching sweats that soak bedclothes, often associated with lymphomas.

Symptoms Due to Metastasis
Symptoms can also arise from the spread of cancer to distant organs.
Bone Pain or Fractures: From metastatic spread to bones (e.g., from breast or prostate cancer).
Neurological Symptoms: Such as headaches, seizures, or dizziness from brain metastases, or jaundice from liver metastases.
Shortness of Breath: Can occur from lung metastases or pleural effusion (fluid around the lung).
It is critical to note that many of these symptoms are non-specific and can be caused by conditions other than cancer. However, their persistence or unexplained nature warrants medical evaluation to determine the underlying cause.

Treatment Modalities in Modern Medicine
The management of cancer in modern medicine is a sophisticated and rapidly evolving field, characterized by a multimodal approach. Treatment selection is personalized based on the type, stage, and molecular characteristics of the cancer, as well as the patient's overall health and preferences. The primary modalities are outlined below.

Surgery
Surgery is the oldest and most frequently used curative treatment for solid, localized tumors.

Purpose: The primary goal is the complete physical removal of the tumor mass along with a margin of surrounding healthy tissue to ensure no malignant cells are left behind. It is also used for debulking (reducing tumor volume), palliation (e.g., relieving obstruction), and prophylaxis (e.g., in high-risk genetic syndromes) [29].
Techniques: These range from traditional open procedures to minimally invasive techniques such as laparoscopy and robot-assisted surgery, which offer shorter recovery times and less morbidity.
Radiation Therapy (Radiotherapy)
Radiotherapy uses high-energy radiation (e.g., X-rays, gamma rays, protons) to kill cancer cells or damage their DNA, inhibiting their ability to divide and grow.
Purpose: It can be used curatively (as a primary treatment or adjuvantly after surgery to eliminate microscopic residual disease), neoadjuvantly (to shrink a tumor before surgery), or palliatively (to relieve symptoms like pain from bone metastases or bleeding) [30].
Techniques: Modern precision techniques, such as Intensity-Modulated Radiation Therapy (IMRT) and Stereotactic Radiosurgery (SRS/SBRT), allow for highly conformal dose delivery, maximizing tumor damage while sparing surrounding healthy tissues.

Systemic Therapies

These treatments use pharmacological agents that travel through the bloodstream to reach cancer cells throughout the body. They are essential for treating metastatic or disseminated disease.

Chemotherapy:
Mechanism: Uses cytotoxic drugs that target rapidly dividing cells by interfering with cell division (e.g., damaging DNA, inhibiting mitotic spindle formation).
Use: Can be curative for some cancers (e.g., leukemias, lymphomas), but is also used for palliation and in combination with other modalities. Its major limitation is toxicity to normal, rapidly dividing tissues (e.g., bone marrow, gastrointestinal mucosa, hair follicles) [31].
Targeted Therapy:
Mechanism: Uses drugs designed to specifically target molecules that are critical for cancer cell growth and survival. These targets include specific gene mutations, overexpressed growth factor receptors, and signaling pathways (e.g., EGFR, ALK, BRAF).
Use: Requires biomarker testing to identify the presence of the target. Examples include tyrosine kinase inhibitors (e.g., imatinib for CML) and monoclonal antibodies (e.g., trastuzumab for HER2-positive breast cancer). They are generally more specific and less toxic than conventional chemotherapy [32].
Immunotherapy:
Mechanism: Harnesses the patient's own immune system to recognize and destroy cancer cells. A major class is immune checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4 antibodies), which block the "brakes" that cancer cells use to evade immune attack.
Use: Has revolutionized the treatment of several advanced cancers, such as melanoma, lung cancer, and renal cell carcinoma. Other approaches include CAR T-cell therapy, cancer vaccines, and cytokine therapy [33].
Hormone Therapy:
Mechanism: Used for cancers that are hormone-sensitive (e.g., breast and prostate cancer). It works by blocking the body's ability to produce hormones or by interfering with how hormones act on cancer cells.
Use: Drugs include tamoxifen and aromatase inhibitors for breast cancer, and androgen deprivation therapy for prostate cancer [34].

Combination and Multimodal Therapy
Most cancer patients receive a combination of these modalities to improve outcomes. For example, a patient might receive neoadjuvant chemotherapy to shrink a tumor, followed by surgery, and then adjuvant radiotherapy or targeted therapy to eliminate any remaining microscopic disease.
The field continues to advance with the development of novel agents, refined radiation techniques, and a growing emphasis on personalized medicine based on comprehensive genomic profiling of individual tumors.

Treatment Modalities in Ayurveda
Ayurveda classifies its therapeutic approaches into three broad categories based on their fundamental mode of action. This classification, found in classical texts like the Charaka Samhita, provides a comprehensive framework for managing diseases, including complex conditions like cancer (*Arbuda*). These modalities address the physical, psychological, and spiritual dimensions of health.

Daivavyapashraya Chikitsa (Divine or Spiritual Therapy)
This modality consists of therapies that are believed to work through divine or cosmic influences, often beyond direct human logical comprehension. It is employed when the etiology of a disease is considered to be of a karmic, spiritual, or supernatural origin (*Daiva*), or when rational therapies are insufficient.
Principles: It is based on the belief that certain ailments result from past actions (*Karma*), planetary influences (*Grahadosha*), or afflictions by supernatural entities (*Bhutabadha*).
Therapeutic Applications:
Mantra (Incantations): The chanting of specific sacred sounds and verses for their vibrational healing effects.
Mani (Use of Gemstones and Talismans): Wearing specific gems or talismans to counteract negative planetary influences.
Mangala (Auspicious Ceremonies): Performing rituals and ceremonies to create a positive and sanctified environment.
Bali (Offerings): Making offerings to pacify perceived negative influences.
Homa (Sacrificial Fire Rituals): Conducting fire ceremonies with specific herbs and offerings to purify the atmosphere and the individual.

Relevance in Cancer Care: In a modern context, this approach can be viewed as providing profound psychological and spiritual solace, fostering a positive mindset, and enhancing the will to fight the disease, which can positively influence the overall healing process [35].

Yuktivyapashraya Chikitsa (Rational or Logical Therapy)
This is the primary and most extensively elaborated modality of Ayurveda, based on rational reasoning (*Yukti*) and the scientific application of therapeutics. It involves a logical diagnosis of the imbalanced *Doshas* and the use of specific substances and procedures to restore balance.
Principles: Treatment is determined by the patient's constitution (*Prakriti*), the nature of the disease imbalance (*Vikriti*), and the qualities of the therapeutic substances.
Therapeutic Applications (Sub-modalities):
***Ahara* (Dietary Therapy):** Prescribing a specific diet (*Pathya*) to pacify aggravated *Doshas* and support digestion (*Agni*), while avoiding foods (*Apathya*) that aggravate the condition.
***Vihara* (Lifestyle Regimen):** Regulating daily (*Dinacharya*) and seasonal (*Ritucharya*) routines, including sleep, exercise, and daily practices.
***Aushadha* (Pharmaceutical Therapy):** The use of herbal, mineral, and herbo-mineral preparations. This includes:
***Shamana* (Palliative Therapy):** Using herbs to pacify aggravated *Doshas* internally(e.g., *Ashwagandha* for Vata, *Guduchi* for Pitta).
***Shodhana* (Purification Therapy):** The five procedures of *Panchakarma* (*Vamana, Virechana, Basti, Nasya, Rakta Mokshana*) to eliminate toxins and vitiated *Doshas* from the body [36].
***Rasayana* (Rejuvenation):** Using immunomodulatory and regenerative substances to promote longevity and vitality after the disease is controlled [37].

Relevance in Cancer Care: *Yuktivyapashraya* forms the core of the physiological management of cancer in Ayurveda, aiming to correct the underlying *Doshic* imbalance, clear toxins (*Ama*), and strengthen the body's inherent healing capacity.

Sattvavajaya Chikitsa (Psychotherapy)
This modality is specifically aimed at controlling and pacifying the mind (*Sattva*). It is considered the Ayurvedic equivalent of psychotherapy and is crucial for managing the mental and emotional stressors associated with a disease like cancer.
Principles: It involves restraining the mind from unwholesome thoughts, desires, and emotions that are detrimental to health.
Therapeutic Applications:
Jnana (Knowledge): Providing right knowledge about the disease and the self to dispel fear and ignorance.
Vijnana (Self-Realization): Cultivating awareness and understanding of one's true nature beyond the physical body and disease.
Dhairya (Courage): Counseling to build fortitude and mental strength.
Smriti (Mindfulness): Practices to enhance recollection and present-moment awareness, preventing the mind from dwelling on negative thoughts.
Dhyana (Meditation): Prescribing meditation practices to calm the mind and reduce stress and anxiety [38].

Relevance in Cancer Care: *Sattvavajaya* is critical for addressing the profound fear, anxiety, depression, and emotional trauma that often accompany a cancer diagnosis and its treatment. It empowers the patient to cultivate a positive mental state, which is considered integral to the healing process.

In conclusion, a comprehensive Ayurvedic approach to cancer would strategically integrate all three modalities: *Yuktivyapashraya* for physiological correction, *Sattvavajaya* for psychological support, and *Daivavyapashraya* for spiritual solace, thereby addressing the patient's well-being on all levels Figures 2.



(Figures:2)

Preventive Measures for Cancer

Cancer prevention encompasses a range of strategies aimed at reducing the risk of developing cancer. These measures are broadly categorized into primary prevention (reducing exposure to risk factors), secondary prevention (early detection of precancerous lesions or cancer at an early stage), and tertiary prevention (managing disease to prevent complications and recurrence). The following evidence-based strategies are recommended by global health organizations.

Lifestyle Modifications

Tobacco Cessation: Avoiding all forms of tobacco—including cigarettes, smokeless tobacco, and secondhand smoke—is the single most effective preventive measure. Tobacco use is linked to at least 15 different cancers. Smoking cessation, at any age, significantly reduces cancer risk over time [39].

Healthy Diet:

Emphasize Plant-Based Foods: A diet rich in fruits, vegetables, whole grains, and legumes provides fiber, vitamins, and phytochemicals with antioxidant and anti-inflammatory properties.

Limit Processed and Red Meat: High consumption of processed meat (e.g., bacon, sausages) and red meat is a convincing cause of colorectal cancer [40].

Limit Ultra-Processed Foods and Sugar-Sweetened Beverages: These contribute to obesity and provide little nutritional value.

Physical Activity and Weight Management: Maintaining a healthy body weight and engaging in regular physical activity (at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity activity per week) independently reduce the risk of several cancers, including breast, colorectal, and endometrial cancer. Physical activity helps regulate hormones and reduce inflammation [41].

Alcohol Moderation: Alcohol consumption is a established risk factor for cancers of the mouth, throat, esophagus, liver, colon, and breast. For cancer prevention, it is best not to drink alcohol. If consumed, limits should be set (e.g., no more than one drink per day for women and two for men, as per some guidelines) [40].

Vaccination and Infection Control

Human Papillomavirus (HPV) Vaccination: Vaccination against HPV, ideally administered before the onset of sexual activity, can prevent the vast majority of cervical cancers, as well as other anogenital and oropharyngeal cancers [42].
Hepatitis B (HBV) Vaccination: Vaccination against HBV prevents chronic hepatitis B infection, a major cause of hepatocellular carcinoma (liver cancer) [43].
Sun and Environmental Protection
Ultraviolet (UV) Radiation Protection: To prevent skin cancers, including melanoma, it is crucial to avoid excessive sun exposure, use broad-spectrum sunscreen (SPF 30 or higher), wear protective clothing, and avoid tanning beds [44].
Reduce Occupational and Environmental Carcinogen Exposure: Following safety protocols to minimize exposure to known carcinogens like asbestos, benzene, arsenic, and radon gas is essential. Testing homes for radon and mitigating high levels can reduce lung cancer risk.

Screening and Early Detection (Secondary Prevention)
While not "prevention" in the primary sense, screening aims to detect precancerous conditions or cancer at an early, treatable stage, thereby preventing cancer deaths.
Cervical Cancer: Regular Pap tests and/or HPV testing.
Breast Cancer: Mammography at recommended intervals based on age and risk.
Colorectal Cancer: Colonoscopy, sigmoidoscopy, or stool-based tests (e.g., FOBT, FIT, FIT-DNA).
Lung Cancer: Low-dose computed tomography (LDCT) for high-risk individuals (e.g., heavy smokers) [45].

Chemoprevention

For individuals at very high risk of certain cancers, medications may be used to reduce risk. Examples include tamoxifen or raloxifene for breast cancer prevention and aspirin for colorectal cancer prevention in specific populations. These interventions require careful risk-benefit analysis under medical supervision Figures 3 [46].

(Figures:3)

Palliative Care in Cancer

Palliative care is a specialized area of medicine focused on improving the quality of life for patients and their families who are facing a serious illness, such as cancer. Its primary goal is to prevent and relieve suffering by addressing physical, psychosocial, and spiritual problems. Importantly, palliative care is **not synonymous with end-of-life care**; it is appropriate at any stage of a serious illness and can be provided concurrently with curative or life-prolonging treatments [47].

Core Components of Palliative Care

Management of Physical Symptoms: A primary focus is the expert management of distressing symptoms caused by the cancer itself or its treatment.

Pain: This is one of the most common and feared symptoms. Palliative care teams use a structured approach, often following the WHO analgesic ladder, to manage pain with non-opioids, opioids, and adjuvant medications, tailored to the individual's needs [48].

Nausea and Vomiting: Caused by chemotherapy, radiation, or the cancer itself. Managed with a variety of antiemetic drugs.

Fatigue: Prevalent and debilitating. Addressed through energy conservation techniques, management of contributing factors (e.g., anemia), and sometimes medications.

Dyspnea (Shortness of Breath): Managed with oxygen, opioids, bronchodilators, and non-pharmacological techniques like fan therapy and breathing exercises.

Anorexia-Cachexia Syndrome: A complex syndrome of weight loss and muscle wasting. Managed with nutritional support, appetite stimulants, and other medications.

Psychosocial and Emotional Support: Palliative care addresses the profound emotional impact of a cancer diagnosis.
Provides counseling for anxiety, depression, and adjustment disorders.
Offers support for patients and families in coping with stress, uncertainty, and the changes brought by the illness.
Facilitates communication between the patient, family, and the healthcare team.

Spiritual Care: Addresses existential distress, questions about meaning, purpose, and hope. Spiritual care practitioners help patients find solace and peace according to their own beliefs and values.

Advance Care Planning: Involves discussions about the patient's goals, values, and preferences for future medical care. This includes completing advance directives and documenting preferences for life-sustaining treatments [49].

Support for Caregivers and Families: Recognizes the immense burden on families and caregivers. Provides them with education, practical support, and emotional respite.

The Evidence for Early Palliative Care

Landmark studies have demonstrated that integrating palliative care early in the course of cancer treatment leads to significant benefits:

Improved Quality of Life: Patients report better symptom control and overall well-being.

Better Mood: Lower rates of depression and anxiety.

Potential for Increased Survival: Some studies, particularly in lung cancer, have shown that early palliative care was associated with longer survival compared to standard care alone [50].

More Aligned Care: Patients are more likely to receive care that aligns with their values and less likely to undergo aggressive, non-beneficial treatments at the end of life.

Reduced Healthcare Costs: Often due to fewer hospitalizations and intensive care unit admissions.

In summary, palliative care is an essential, patient-centered component of comprehensive cancer care. It should be integrated from the point of diagnosis alongside oncology treatments to alleviate suffering and improve the quality of life for all affected by cancer Figures 4.



(Figures:4)

Conclusion

Cancer remains one of the most formidable challenges to global health, characterized by its complex pathophysiology and profound physical and psychosocial impact. This review has delineated the landscape of cancer from the distinct yet potentially complementary perspectives of modern oncology and Ayurveda. Modern medicine provides a detailed understanding of the molecular and cellular hallmarks of cancer, leading to sophisticated diagnostic tools and targeted treatments such as immunotherapy and precision oncology. However, these approaches are often associated with significant toxicity, financial cost, and the persistent challenge of therapeutic resistance.

Concurrently, Ayurveda offers a holistic paradigm, viewing cancer as a manifestation of systemic imbalance involving the *Tridoshas*, *Agni*, and *Ama*. Its therapeutic arsenal, comprising *Shodhana* (purification), *Shamana* (palliation), and *Rasayana* (rejuvenation), aims to restore physiological equilibrium and strengthen the body's inherent healing capacity. The principles of *Daivavyapashraya*, *Yuktivyapashraya*, and *Sattvavajaya Chikitsa* further underscore a comprehensive approach that addresses the physical, mental, and spiritual dimensions of the disease.

The convergence of these two systems holds immense promise for the future of oncology. An integrative model, where evidence-based Ayurvedic interventions are synergistically combined with modern anti-cancer therapies, can potentially mitigate treatment-related side effects, enhance quality of life, improve resilience, and possibly modulate disease outcomes. Palliative care principles, central to both systems, further emphasize the shared goal of holistic patient-centered care.

Future progress hinges on robust scientific research to validate the safety, efficacy, and mechanisms of action of Ayurvedic therapies through well-designed preclinical and clinical trials. Fostering a collaborative dialogue between oncologists and Ayurvedic practitioners is essential to develop safe, effective, and standardized integrative protocols. Ultimately,

transcending the boundaries of a single medical system to embrace a truly holistic, evidence-based, and patient-centric framework offers the best hope for preventing, managing, and overcoming the burden of cancer.

References

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70. doi: 10.1016/s0092-8674(00)81683-9.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
3. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059.
4. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993 Apr;9(4):138-41. doi: 10.1016/0168-9525(93)90209-z.
5. Weinberg RA. The Biology of Cancer. 2nd ed. New York: Garland Science; 2014.
6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834.
7. Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016 Sep;48(3):889-902. doi: 10.1183/13993003.00359-2016.
8. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6.
9. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 Mar;73 Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288.
10. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356-387. doi: 10.1016/j.ejca.2018.07.005.
11. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012 Aug;13(8):790-801. doi: 10.1016/S1470-2045(12)70211-5.
12. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004 Aug 23;23(38):6445-70. doi: 10.1038/sj.onc.1207714.
13. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122.
14. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003 Oct;3(10):733-44. doi: 10.1038/nrc1190.
15. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020 Feb;8(2):e180-e190. doi: 10.1016/S2214-109X(19)30488-7.
16. Greinert R, de Vries E, Erdmann F, Espina C, Auvinen A, Kesminiene A, Schüz J. European Code against Cancer 4th Edition: Ultraviolet radiation and cancer. Cancer Epidemiol. 2015 Dec;39 Suppl 1:S75-83. doi: 10.1016/j.canep.2014.12.006.
17. Rushton L, Hutchings SJ, Fortunato L, et al. Occupational cancer burden in Great Britain. Br J Cancer. 2012 Jun 19;107 Suppl 1(Suppl 1):S3-S7. doi: 10.1038/bjc.2012.112.
18. Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008 Aug;67(3):253-6. doi: 10.1017/S002966510800712X.
19. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K; International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016 Aug 25;375(8):794-8. doi: 10.1056/NEJMsr1606602.
20. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019 May;69(3):184-210. doi: 10.3322/caac.21557.
21. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007 Sep;18(9):1437-49. doi: 10.1093/annonc/mdm056.
22. Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng KK, Marshall T. The importance of anaemia in diagnosing colorectal cancer: a case-control study using electronic primary care records. Br J Cancer. 2008 Jan 15;98(2):323-7. doi: 10.1038/sj.bjc.6604165.

23. Hamilton W, Sharp D. Diagnosis of lung cancer in primary care: a structured review. Fam Pract. 2004 Dec;21(6):605-11. doi: 10.1093/fampra/cmh605.
24. Jones RV. Use of alarm symptoms in primary care. BMJ. 2007 Oct 20;335(7624):784. doi: 10.1136/bmj.39345.439769.AD.
25. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol. 1996 May;34(5 Pt 1):839-47. doi: 10.1016/s0190-9622(96)90071-7.
26. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7.
27. Berger AM, Mooney K, Alvarez-Perez A, et al. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39. doi: 10.6004/jnccn.2015.0122.
28. Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer. 2005 Nov;13(11):870-7. doi: 10.1007/s00520-005-0825-4.
29. Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol. 2011 Sep;104(4):379-85. doi: 10.1002/jso.21876.
30. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193-9. doi: 10.7150/ijms.3635.
31. Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. 2005 Jan;5(1):65-72. doi: 10.1038/nrc1529.
32. Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094.
33. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020 Nov;20(11):651-668. doi: 10.1038/s41577-020-0306-5.
34. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015 Oct 3;386(10001):1341-52. doi: 10.1016/S0140-6736(15)61074-1.
35. Murthy ARV, Singh RH. The concepts of Daiva and Purushakara in Ayurveda. Anc Sci Life. 1987 Jul;7(1):1-7.
36. Rastogi S. Building bridges between Ayurveda and modern science. Int J Ayurveda Res. 2010 Jan;1(1):41-6. doi: 10.4103/0974-7788.59943.
37. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Phytother Res. 1999 Jun;13(4):275-91. doi: 10.1002/(SICI)1099-1573(199906)13:4<275::AID-PTR510>3.0.CO;2-S.
38. Tripathi JS, Singh RH. Concept of Sattvavajaya Chikitsa (Psychotherapy) in Ayurveda. Anc Sci Life. 1998 Oct;18(2):153-9.
39. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
40. World Cancer Research Fund / American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. Available at: dietandcancerreport.org.
41. McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical Activity in Cancer Prevention and Survival: A Systematic Review. Med Sci Sports Exerc. 2019;51(6):1252-1261. doi:10.1249/MSS.0000000000001937.
42. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5(5):CD009069. Published 2018 May 9. doi:10.1002/14651858.CD009069.pub3.
43. Chang MH. Hepatitis B virus and cancer prevention. Recent Results Cancer Res. 2011;188:75-84. doi:10.1007/978-3-642-10858-7_6.
44. Leiter U, Keim U, Garbe C. Epidemiology of Skin Cancer: Update 2019. Adv Exp Med Biol. 2020;1268:123-139. doi:10.1007/978-3-030-46227-7_6.
45. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184-210. doi:10.3322/caac.21557.
46. Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015;26(1):47-57. doi:10.1093/annonc/mdu225.
47. World Health Organization (WHO). Palliative Care. [Key Facts]. Retrieved from: https://www.who.int/news-room/fact-sheets/detail/palliative-care
48. Swarm RA, Paice JA, Anghelescu DL, et al. Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(8):977-1007. doi:10.6004/jnccn.2019.0038.

49. National Consensus Project for Quality Palliative Care. Clinical Practice Guidelines for Quality Palliative Care, 4th Edition. Richmond, VA: National Coalition for Hospice and Palliative Care; 2018. Available at: https://www.nationalcoalitionhpc.org/ncp
50. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742. doi:10.1056/NEJMoa1000678.